An Open-label Comparison of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Primary Open Angle Glaucoma
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2016
At a glance
- Drugs Latanoprost (Primary) ; Latanoprost
- Indications Glaucoma; Ocular hypertension
- Focus Therapeutic Use
- Sponsors Peregrine Ophthalmic
- 20 Apr 2016 Status changed from active, no longer recruiting to completed.
- 23 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 08 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.